Updates in Pharmacologic Strategies in ADHD, An Issue of ChildAnd Adolescent Psychiatric Clinics of North America, 1st Edition

Author :
Edited by Jeffrey H. Newcorn, MD and Timothy E. Wilens, MD
In this issue of Child and Adolescent Psychiatric Clinics, guest editors Drs. Jeffrey H. Newcorn and Timothy E. Wilens bring their considerable expertise to the topic of Updates in Pharmacol ...view more
In this issue of Child and Adolescent Psychiatric Clinics, guest editors Drs. Jeffrey H. Newcorn and Timothy E. Wilens bring their considerable expertise to the topic of Updates in Pharmacologic Strategies in ADHD. Top experts in the field cover key topics such as PK of stimulants pharmacogenomics, stimulants, nonstimulants, neurotherapeutics, and more. 
ISBN :
9780323919913
Publication Date :
17-06-2022
Add to Cart
In this issue of Child and Adolescent Psychiatric Clinics, guest editors Drs. Jeffrey H. Newcorn and Timothy E. Wilens bring their considerable expertise to the topic of Updates in Pharmacologic Strategies in ADHD. Top experts in the field cover key topics such as PK of stimulants pharmacogenomics, stimulants, nonstimulants, neurotherapeutics, and more. 

Key Features
  • Contains 15 relevant, practice-oriented topics including special groups: ADHD+, such as mood/ dysregulation and disruptive behavior; SUD; autism; tics, Tourette syndrome, and anxiety; sleep; cardiovascular; college-aged; transitional-aged youth; adults; and more. 

  • Provides in-depth clinical reviews on pharmacologic strategies in ADHD, offering actionable insights for clinical practice. 

  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. 


Author Information
Edited by Jeffrey H. Newcorn, MD, Professor of Psychiatry and Pediatrics, Director, Division of ADHD and Learning Disorders, Icahn School of Medicine at Mount Sinai, Director, Pediatric Psychopharmacology, Mount Sinai Health System; Timothy E. Wilens, MD, Chief of the Division of Child and Adolescent Psychiatry and Co-director of the Center for Addiction Medicine; Massachusetts General Hospital (MGH) and MGH Trustees Chair in Addiction Medicine and Professor of Psychiatry, Harvard Medical School